# Cannabix Technologies Launches Marijuana Breath Test (MBT)

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/marijuana-breath-test-technology-workplace-screening/
> **Published:** 2026-03-16T08:43:45-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:56-04:00
> **Clinical Summary:** Explore marijuana breath test technology detecting recent cannabis use for workplace safety and clinical assessment with a 4-hour detection window.

---

✦ New

 CED Clinical Relevance
 #45
 Clinical Context
 Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape.

PolicyTHCSafetyIndustry

 Why This Matters
 Clinicians treating patients with substance use disorders or evaluating impairment now have access to a rapid, non-invasive objective measure of recent [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) that could improve diagnostic accuracy and treatment monitoring. The 4-hour detection window aligns with the period of acute impairment, providing clinicians with temporally relevant information for assessing current intoxication status in emergency or occupational health settings. However, clinicians should recognize that breath THC levels do not correlate perfectly with impairment or clinical effects, so test results must be interpreted alongside clinical assessment rather than used as standalone markers.

 Clinical Summary
 

Cannabix Technologies has launched a commercial breath test device that detects delta-9 THC above 5 picograms per liter, with a detection window of approximately 4 hours post-consumption. The marijuana breath test (MBT) system is being rolled out in phases to employers through Omega Labs, positioning it as a workplace screening tool analogous to alcohol breathalyzers. This technology addresses a long-standing gap in workplace drug testing by offering real-time, non-invasive detection of recent cannabis use, which is increasingly relevant as [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands across jurisdictions. For clinicians, this development has implications for patients in safety-sensitive occupations and for those undergoing workplace screening, as the test’s 4-hour window aligns more closely with impairment duration than traditional urine tests that detect cannabinoids for weeks. Clinicians should be aware that patients who use cannabis medically or recreationally may face workplace consequences based on this breath test technology, even in jurisdictions where cannabis is legal. Practitioners should counsel patients about the detection window and occupational risks when discussing cannabis use, particularly for those in industries with mandatory drug testing programs.

 Dr. Caplan’s Take
 “While a breath test for THC is technically useful for workplace safety protocols, we need to be clear with our patients and employers that a positive result tells us someone used cannabis recently, not whether they’re impaired right now or unfit for duty—that distinction matters enormously in my clinic when I’m counseling people about their employment and their actual functional status.”

 Clinical Perspective
 
 

The emergence of breath-based tetrahydrocannabinol detection technology raises important considerations for clinicians advising patients on cannabis use and impairment. While a quantifiable breath test for delta-9 THC may seem analogous to alcohol breathalyzers, critical differences complicate interpretation: breath THC levels do not reliably correlate with impairment, cognitive function, or driving ability the way blood alcohol concentration does, and detection windows vary substantially based on individual metabolism, frequency of use, and product type. Clinicians should understand that a positive breath test result reflects recent cannabis exposure but cannot determine functional impairment, intoxication status, or safety for tasks like driving or operating machinery. When counseling patients—particularly those in safety-sensitive occupations or facing workplace screening—providers should clarify that detection capability does not equate to validated impairment measurement, and that workplace or legal policies based on such tests may not

 

 

💬 Join the Conversation

 

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

 

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Cannabix+Technologies+Announces+Commercial+Launch+of+Marijuana+Breath+Test+%28MBT%29+%40drcaplan&url=https%3A%2F%2Fwww.stocktitan.net%2Fnews%2FBLOZF%2Fcannabix-technologies-announces-commercial-launch-of-marijuana-7w0fnnxj4r7o.html)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.stocktitan.net%2Fnews%2FBLOZF%2Fcannabix-technologies-announces-commercial-launch-of-marijuana-7w0fnnxj4r7o.html)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Cannabix+Technologies+Announces+Commercial+Launch+of+Marijuana+Breath+Test+%28MBT%29+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.stocktitan.net%2Fnews%2FBLOZF%2Fcannabix-technologies-announces-commercial-launch-of-marijuana-7w0fnnxj4r7o.html)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

📰 Source: [https://www.stocktitan.net/news/BLOZF/cannabix-technologies-announces-commercial-launch-of-marijuana-7w0fnnxj4r7o.html](https://www.stocktitan.net/news/BLOZF/cannabix-technologies-announces-commercial-launch-of-marijuana-7w0fnnxj4r7o.html)

 Further Reading
 CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/)
 Cannabis Policy Wire[AM Policy Update: March 16, 2026](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/)
 Evidence WatchEndocannabinoid System Research: Cannabinoids in Children

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Federally Funded Study Reveals Marijuana Breathalyzer Breakthrough With 3-D Printed …](https://cedclinic.com/cannabis-impairment-detection-technology-breakthrough/)

Discover the latest advancements in marijuana breathalyzer technology and its implications for cannabis detection.

[Read the breakthrough study](https://cedclinic.com/cannabis-impairment-detection-technology-breakthrough/)

[With Marijuana Rescheduling Still Pending, Federal Workplace Drug Testing Rules Aren't …](https://cedclinic.com/federal-workplace-drug-testing-policies-marijuana-update/)

Learn about the challenges and current status of federal workplace drug testing rules amid marijuana rescheduling debates.

[Explore workplace drug testing rules](https://cedclinic.com/federal-workplace-drug-testing-policies-marijuana-update/)

[THC levels in blood and urine are "unreliable" indicators of driving impairment – leafie](https://cedclinic.com/cannabis-impairment-testing-challenges-driving-safety/)

Understand why THC levels in traditional tests may not reliably indicate impairment and the need for new detection methods.

[Read about THC impairment indicators](https://cedclinic.com/cannabis-impairment-testing-challenges-driving-safety/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
